Centre for Virology, Vaccinology and Therapeutics
Translational research centre (est. 2020) based at the Hong Kong Science and Technology Park focused on diagnostics, vaccines, antivirals and preclinical platforms for infectious diseases. Combines laboratory virology, human organoid models, transgenic animal models, analytical chemistry and computational screening to support discovery, preclinical evaluation and technology translation.
Industries
Nr. of Employees
medium (51-250)
Centre for Virology, Vaccinology and Therapeutics
Patents
Targeting papain-like protease for broad-spectrum coronaviruses inhibition
US-11986478-B2
View Details
Targeting papain-like protease for broad-spectrum coronaviruses inhibition
US-11986478-B2
View DetailsProducts
Organoid-based research platforms
Human respiratory and intestinal organoids used to model viral infection, evaluate antibody and vaccine efficacy, and support translational preclinical applications.
Licensable vaccine and therapeutic technologies
A portfolio of licensable technologies including live-attenuated systems, mucosal and RNA scaffold vaccine platforms, neutralizing antibodies and antiviral compound technologies.
Respiratory Organoid Platform
Organoid culture product development, organoid-based services, and disease model construction provided by BiomOrgan Limited.
Flu-based viral vector intranasal vaccine
An intranasal vaccine developed by Hong Kong Universal Biologicals Company Limited (HKUBio) for influenza, COVID-19, and other future respiratory viral diseases.
Human Respiratory Tract Organoids
Organoid models designed to mimic human tissue structures, facilitating detailed investigations into viral replication and variant behaviors.
DelNS1 Live Attenuated Vaccine System for Influenza and Other Respiratory Viral Diseases, and for Gastric Diseases Through Shared Mucosal Immune System
A live attenuated vaccine system utilizing the DelNS1 platform designed for influenza and other respiratory viral diseases, as well as gastric diseases.
Organoid-based research platforms
Human respiratory and intestinal organoids used to model viral infection, evaluate antibody and vaccine efficacy, and support translational preclinical applications.
Licensable vaccine and therapeutic technologies
A portfolio of licensable technologies including live-attenuated systems, mucosal and RNA scaffold vaccine platforms, neutralizing antibodies and antiviral compound technologies.
Respiratory Organoid Platform
Organoid culture product development, organoid-based services, and disease model construction provided by BiomOrgan Limited.
Flu-based viral vector intranasal vaccine
An intranasal vaccine developed by Hong Kong Universal Biologicals Company Limited (HKUBio) for influenza, COVID-19, and other future respiratory viral diseases.
Human Respiratory Tract Organoids
Organoid models designed to mimic human tissue structures, facilitating detailed investigations into viral replication and variant behaviors.
DelNS1 Live Attenuated Vaccine System for Influenza and Other Respiratory Viral Diseases, and for Gastric Diseases Through Shared Mucosal Immune System
A live attenuated vaccine system utilizing the DelNS1 platform designed for influenza and other respiratory viral diseases, as well as gastric diseases.
Services
Analytical and discovery support for small molecules, metabolomics and lipidomics, drug–target interaction studies, structure determination, purity assessment and integrated in silico–experimental screening.
Analytical and discovery support for small molecules, metabolomics and lipidomics, drug–target interaction studies, structure determination, purity assessment and integrated in silico–experimental screening.
Expertise Areas
- Vaccine development (mucosal, DNA, RNA, live attenuated)
- Antiviral and antibody therapeutics discovery
- Preclinical model development (organoids and transgenic animals)
- Diagnostic assay development and multiplex pathogen detection
Key Technologies
- Human organoid culture models (respiratory and intestinal)
- Transgenic mouse models
- Structure-based virtual screening and docking
- Nuclear magnetic resonance (NMR)
News & Updates
Participation and presentation of vaccine and therapeutic innovations at BIOHK2025.
Report on discovery of a bispecific inhibitor active against human-pathogenic coronaviruses, including strains resistant to existing treatments.
Collaborative development of organoid-based systems to evaluate antibody and vaccine efficacy to support translational testing.
Announcement of development of a nasal-spray H5N1 avian influenza vaccine in collaboration with a state key laboratory.
Professor Kwok-Yung Yuen recognized as top scientist in microbiology and leading researcher in China
Recognition of the centre's managing director in the Research.com Best Scientists rankings.
Report of awards and recognition at the 49th International Exhibition of Inventions in Geneva.
Participation and presentation of vaccine and therapeutic innovations at BIOHK2025.
Report on discovery of a bispecific inhibitor active against human-pathogenic coronaviruses, including strains resistant to existing treatments.
Collaborative development of organoid-based systems to evaluate antibody and vaccine efficacy to support translational testing.
Announcement of development of a nasal-spray H5N1 avian influenza vaccine in collaboration with a state key laboratory.
Professor Kwok-Yung Yuen recognized as top scientist in microbiology and leading researcher in China
Recognition of the centre's managing director in the Research.com Best Scientists rankings.
Report of awards and recognition at the 49th International Exhibition of Inventions in Geneva.